Sonoma Pharmaceuticals Inc SNOA has added Salus Medical as an additional distribution partner in the U.S for dental care.
- The Company has also expanded its oral and dental care lines to China via a partnership deal with Anlicare International.
- Sonoma entered into a non-exclusive agreement with Salus Medical to distribute Endocyn root canal irrigant through their existing dental channels.
- In addition, Salus Medical will expand on its dermatology offerings with Sonoma's Microcyn RX and Regenacyn Plus products and have non-exclusive distribution rights for Microcyn wound care products.
- Additionally, Sonoma and Anlicare agreed to cooperate to complete the regulatory work necessary to obtain licenses in China to distribute Sonoma's Microcyn technology-based dental and oral products.
- Anlicare will bear the regulatory costs, and in return, Sonoma agreed to grant Anlicare exclusive rights for selling and distributing oral and dental care products in China.
- In September, Sonoma launched its first OTC products in the U.S. on Amazon and a new consumer-focused product on Amazon in Europe.
- Price Action: SNOA shares are down 12.2% at $3.73 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in